Arvinas, ARV-102, LRRK2, Parkinson’s Disease, Progressive Supranuclear Palsy, PSP, PROTAC, Targeted Protein Degradation, Protein Degrader

NEW HAVEN, Conn. — October 1, 2026 Arvinas, Inc. announced that novel biomarker data from the Phase 1 clinical...